sur ABIONYX (EPA:ABNX)
ABIONYX Pharma presents the results of the RACERS study
ABIONYX Pharma announced that the results of its RACERS study will be presented at the American Society of Nephrology Kidney Week in 2024. The phase 2b study focuses on the treatment of brain fog associated with sepsis, showing positive effects on cognitive impairment.
The data reveal that CER-001, a biologic, alleviates brain dysfunction by regulating the enzyme IDO1, which is linked to kynurenine metabolism, which is strongly involved during inflammation.
The results indicate an increase in tryptophan and kynurenic acid, suggesting neuroprotection. Professor Loreto Gesualdo pointed out that CER-001 could improve cognitive functions in septic patients.
These results support the potential of CER-001 in the treatment of neuroinflammation, opening the way to new indications.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIONYX